Norges Bank
RNAM

Norges Bank’s Avidity Biosciences RNAM Stock Holding History

Norges Bank’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,046,388
Closed -$220M – 1109
2025
Q4 		$220M Buy
+3,046,388
New +$197M 0.02% 494
2025
Q3 		– Sell
-995,118
Closed -$28.3M – 1232
2025
Q2 		$28.3M Buy
995,118
+156,900
+19% +$4.68M ﹤0.01% 1134
2025
Q1 		$24.7M Buy
838,218
+113,431
+16% +$3.53M ﹤0.01% 1160
2024
Q4 		$21.1M Sell
724,787
-322,069
-31% -$13.5M ﹤0.01% 1225
2024
Q3 		$48.1M Buy
+1,046,856
New +$45.4M 0.01% 988
2023
Q2 		– Sell
-290,500
Closed -$4.46M – 2099
2023
Q1 		$4.46M Buy
290,500
+205,400
+241% +$4.52M ﹤0.01% 1790
2022
Q4 		$1.89M Buy
+85,100
New +$1.27M ﹤0.01% 1976

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Norges Bank's RNAM Position: Q1 2026 in Review

Norges Bank sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 3,046,388 shares — an estimated $220M sold.

Norges Bank first reported a position in RNAM in Q4 2022 and held it in 7 quarters. The position peaked at $220M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Norges Bank reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Norges Bank sold 3,046,388 Avidity Biosciences shares in Q1 2026, an estimated $220M.
  • Norges Bank first reported a position in Avidity Biosciences in Q4 2022 and held it in 7 quarters.
  • Norges Bank's Avidity Biosciences position peaked at $220M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.